title: Non-conventional respiratory support modalities applicable in the older child. High frequency ventilation and liquid ventilation.
abstract: HFV, LV, and several other novel therapies offer promise to adults and children that the mortality associated with respiratory failure may be affected. Although there are several forms of HFV, HFOV is presently gaining favor in the treatment of severe respiratory failure and has generally supplanted HFJV in pediatric critical care. HFOV has the advantage of having an active expiratory phase, which helps to minimize air trapping and better modulate mean lung volume. Ventilators with sufficient power to perform HFOV in adults are currently under investigation, although there is a growing experience in using current ventilators in larger patients. To date, however, demonstration of lowered mortality with HFOV is lacking although intermediate outcome indicators are improved. PLV also offers promise in the treatment of ARF through its drastic ability to improve oxygenation, ventilation, and compliance in many lung injury models. Human trials are presently underway, but the optimal delivery of this novel therapy still necessitates extensive investigation. TLV is likely even more removed from general clinical application given the necessity of developing a new generation of ventilators for the delivery of liquid tidal volumes. How these and other modalities may piece together to improve the condition of our patients who have respiratory failure remains to be seen, but certainly, present and future investigation will be intriguing for years to come.
authors.affiliation: Department of Pediatrics, University of California, Davis, School of Medicine, Sacramento, USA. hjkallas@ucdavis.edu
authors.forename: H J
authors.initials: HJ
authors.lastname: Kallas
mesh_terms: D000208:Acute Disease; D000328:Adult; D000367:Age Factors; D002648:Child; D005466:Fluorocarbons / Q000627:therapeutic use*; D006612:High-Frequency Ventilation / Q000379:methods*; D006801:Humans; D011659:Pulmonary Gas Exchange; D012121:Respiration, Artificial / Q000379:methods*; D012128:Respiratory Distress Syndrome / Q000378:metabolism / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D013990:Tidal Volume; D016896:Treatment Outcome
chemical_list: D005466:Fluorocarbons